Junshi and Coherus’s Toripalimab Receive the US FDA’s Breakthrough Therapy Designation as 1L Treatment of Nasopharyngeal Carcinoma Published: Aug 13, 2021 | Tags: Junshi, Coherus, Toripalimab, US, FDA, Breakthrough Therapy […]readmore
Tags : Dyadic
Shots: Dyadic to receive $10M up front in cash & stock and ~$4M in reimbursements for pre/ clinical development costs for DYAI-100 vaccine & ~ $33M in milestone along with […]readmore